ArticleInternational journal of molecular sciences2026
Protective Effects of Policosanol and Atorvastatin Co-Supplementation Against High-Cholesterol and High-Galactose Diet-Induced Metabolic and Organ Dysfunction in Zebrafish.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study compares the effects of policosanol (Poli), atorvastatin (Ator), and their combination (Poli+Ator) in mitigating high-cholesterol and high-galactose (HCHG) diet-induced metabolic stress and organ damage in zebrafish. After 22 weeks of feeding, the lowest survival probability was observed in the Ator-supplemented group (0.64). In comparison, the Poli and Poli+Ator-supplemented groups showed higher survival probabilities of 0.76 and 0.71, respectively. Compared with Poli, Ator supplementation had a greater effect in mitigating HCHG-induced dyslipidemia. Nonetheless, Poli+Ator demonstrated a significantly greater effect than Ator and Poli in reducing total blood cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), and in elevating the HDL-C/TC ratio. No significant effect of Ator supplementation was observed on the HCHG-induced elevations in blood glucose and malondialdehyde (MDA) levels or the diminished sulfhydryl content; however, Poli alone and Poli+Ator significantly improved blood glucose, MDA, and sulfhydryl content. Consistently, the non-significant effect of Ator on the amputated tail fin regeneration was substantially improved by the Poli+Ator supplementation. In addition, Poli and Poli+Ator markedly reduce liver steatosis, neutrophil infiltration, and interleukin (IL)-6 production, while inhibiting the generation of oxidative species and senescent-positive cells in the kidney and preventing intestinal fibrosis. Also, Poli and Poli+Ator substantially minimize HCHG-triggered oxidative stress in reproductive organs, enhance spermatozoa count in the testis and substantially improve the embryo-producing ability of zebrafish. The study outlines the beneficial effect of Poli and Poli+Ator in mitigating HCHG-induced dyslipidemia, organ damage, and reproductive health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.